August 8, 2024 07:59 AM EDT

Entero Therapeutics turns the lights off as creditors come calling

Amber Tong

Just months after Entero Therapeutics completed the merger that brought in its new lead candidate, the debt inherited from the deal is creeping up on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Entero Therapeutics turns the lights off as creditors come calling

Amber Tong

Sign up to read this article for free.

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

CDMO Serán sets out to build first commercial facility, with a $200M investment led by Bain Capital

Breaking down silos with a new quantitative approach to drug development

En­tero Ther­a­peu­tics turns the lights off as cred­i­tors come call­ing

Amber Tong

Sign up to read this article for free.

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Entero Therapeutics turns the lights off as creditors come calling

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

CDMO Serán sets out to build first commercial facility, with a $200M investment led by Bain Capital

Breaking down silos with a new quantitative approach to drug development